InspireMD Inc. (NSPR): Price and Financial Metrics


InspireMD Inc. (NSPR): $3.76

-0.07 (-1.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NSPR POWR Grades


  • Growth is the dimension where NSPR ranks best; there it ranks ahead of 73.22% of US stocks.
  • NSPR's strongest trending metric is Growth; it's been moving down over the last 116 days.
  • NSPR's current lowest rank is in the Stability metric (where it is better than 3.64% of US stocks).

NSPR Stock Summary

  • NSPR has a higher market value than only 5.34% of US stocks; more precisely, its current market capitalization is $30,202,738.
  • In terms of volatility of its share price, NSPR is more volatile than 99.7% of stocks we're observing.
  • InspireMD Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -170.39%, greater than the shareholder yield of just 1.53% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to InspireMD Inc, a group of peers worth examining would be LQDA, BBI, NBRV, SNES, and IGC.
  • Visit NSPR's SEC page to see the company's official filings. To visit the company's web site, go to www.inspiremd.com.

NSPR Valuation Summary

  • NSPR's price/sales ratio is 13.9; this is 286.11% higher than that of the median Healthcare stock.
  • Over the past 125 months, NSPR's price/sales ratio has gone NA NA.
  • Over the past 125 months, NSPR's EV/EBIT ratio has gone up 2946.3.

Below are key valuation metrics over time for NSPR.

Stock Date P/S P/B P/E EV/EBIT
NSPR 2019-11-25 0.8 0.4 -0.3 0.4
NSPR 2018-09-07 1.3 1.1 -0.4 0.3
NSPR 2015-01-29 9.3 -5.1 -1.3 -1.5
NSPR 2013-11-29 15.8 7.2 -3.6 -6.6
NSPR 2012-02-15 13.5 8.9 -9.7 -9.9
NSPR 2011-11-16 18.8 12.5 -13.5 -14.3

NSPR Growth Metrics

  • The 5 year net cashflow from operations growth rate now stands at 40.02%.
  • The 3 year net income to common stockholders growth rate now stands at 34.42%.
  • Its 4 year cash and equivalents growth rate is now at 57.13%.
NSPR's revenue has moved up $557,000 over the prior 49 months.

The table below shows NSPR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 2.457 -10.368 -11.809
2020-12-31 2.485 -9.081 -10.544
2020-09-30 3.34 -8.449 -9.248
2020-09-30 3.34 -8.449 -9.248
2020-06-30 3.299 -7.265 -9.085
2020-03-31 4.34 -8.679 -8.811

NSPR Price Target

For more insight on analysts targets of NSPR, see our NSPR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.50 Average Broker Recommendation 1.5 (Moderate Buy)

NSPR Stock Price Chart Interactive Chart >

Price chart for NSPR

NSPR Price/Volume Stats

Current price $3.76 52-week high $22.20
Prev. close $3.83 52-week low $3.60
Day low $3.75 Volume 105,100
Day high $3.86 Avg. volume 898,296
50-day MA $4.98 Dividend yield N/A
200-day MA $7.47 Market Cap 29.73M

InspireMD Inc. (NSPR) Company Bio


InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. is headquartered in Tel Aviv, Israel.


NSPR Latest News Stream


Event/Time News Detail
Loading, please wait...

NSPR Latest Social Stream


Loading social stream, please wait...

View Full NSPR Social Stream

Latest NSPR News From Around the Web

Below are the latest news stories about InspireMD Inc that investors may wish to consider to help them evaluate NSPR as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning!

William White on InvestorPlace | July 22, 2021

Should I Avoid InspireMD Inc (NSPR)?

No summary available.

Insider Monkey | June 13, 2021

InspireMD Announces Warrants Exchange Listing Transfer to Nasdaq

Tickers to be NSPRW and NSPRZ Tickers to be NSPRW and NSPRZ

GlobeNewswire | May 27, 2021

InspireMD Announces Warrants Exchange Listing Transfer to NasdaqTickers to be NSPRW and NSPRZ

InspireMD, Inc., developer of the CGuard Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced the Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market.

BioSpace | May 26, 2021

Will InspireMD (NASDAQ:NSPR) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | May 24, 2021

Read More 'NSPR' Stories Here

NSPR Price Returns

1-mo -21.75%
3-mo -29.06%
6-mo -62.63%
1-year -45.32%
3-year -97.61%
5-year -100.00%
YTD -26.47%
2020 -68.44%
2019 -86.42%
2018 -96.45%
2017 -94.88%
2016 -88.64%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8302 seconds.